A5030982118- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- Cytokine Signaling Pathways and Interactions
- Systemic Lupus Erythematosus Research
- Polyomavirus and related diseases
- Immunotherapy and Immune Responses
- Lipoproteins and Cardiovascular Health
- Rheumatoid Arthritis Research and Therapies
- Neuroinflammation and Neurodegeneration Mechanisms
- Monoclonal and Polyclonal Antibodies Research
- interferon and immune responses
- Cancer Treatment and Pharmacology
- Immune Response and Inflammation
- Fibromyalgia and Chronic Fatigue Syndrome Research
- T-cell and B-cell Immunology
- Myasthenia Gravis and Thymoma
- Neurogenesis and neuroplasticity mechanisms
- Ocular Diseases and Behçet’s Syndrome
- Atherosclerosis and Cardiovascular Diseases
- Nerve injury and regeneration
- Immune Cell Function and Interaction
- Reproductive Biology and Fertility
- Parkinson's Disease Mechanisms and Treatments
- Amyotrophic Lateral Sclerosis Research
- Genetic Neurodegenerative Diseases
Albstadt-Sigmaringen University
2008-2023
Heinrich Heine University Düsseldorf
2002-2020
GTx (United States)
2020
Medical University of Graz
2019
Charité - Universitätsmedizin Berlin
2018
St. Josef-Hospital
2018
Max Planck Institute of Neurobiology
2000-2008
FH Aachen
2007
Düsseldorf University Hospital
2003-2005
Max Planck Society
2002-2004
Abstract Background The diagnostic and pathophysiological relevance of antibodies to aquaporin-4 (AQP4-Ab) in patients with neuromyelitis optica spectrum disorders (NMOSD) has been intensively studied. However, little is known so far about the clinical impact AQP4-Ab seropositivity. Objective To analyse systematically paraclinical features associated NMO Caucasians a stratified fashion according patients' serostatus. Methods Retrospective study 175 Caucasian (AQP4-Ab positive 78.3%). Results...
To analyze whether 1 of the 2 apheresis techniques, therapeutic plasma exchange (PE) or immunoadsorption (IA), is superior in treating neuromyelitis optica spectrum disorder (NMOSD) attacks and to identify predictive factors for complete remission (CR).This retrospective cohort study was based on registry German Neuromyelitis Optica Study Group, a nationwide network established 2008. It recruited patients with diagnosed according 2006 Wingerchuk criteria aquaporin-4...
Copolymer 1 (COP), a standardized mixture of synthetic polypeptides consisting l -glutamic acid, -lysine, -alanine, and -tyrosine, has beneficial effects in multiple sclerosis experimental autoimmune encephalomyelitis. We selected panel 721 COP-reactive T cell lines (TCL) from the blood COP-treated untreated patients healthy donors by using split-well cloning technique. All TCL with COP proliferated response to but not myelin basic protein (MBP). Conversely, 31 control MBP COP. used...
Glatiramer acetate (GA, Copaxone [Teva Pharmaceuticals, Kansas City, MO], formerly known as copolymer-1) and interferon- (IFN)-β are both used for the immunomodulatory treatment of multiple sclerosis, but they act in different ways. Four major mechanisms GA have been identified: 1) competition with myelin-basic protein (MBP) binding to histocompatibility complex (MHC) molecules; 2) GA/MHC MBP/MHC T-cell receptor; 3) partial activation tolerance induction MBP-specific T cells (action an...
<b><i>Background: </i></b> Recent data suggest that statins may be potent immunomodulatory agents. In order to evaluate the potential role of as immunomodulators in MS, authors studied their immunologic effects vitro and compared them interferon (IFN)β-1b. <b><i>Methods: Peripheral blood mononuclear cells (PBMC) obtained from untreated or IFNβ-1–treated patients with relapsing-remitting MS healthy donors (HD) T were stimulated concanavalin A, phytohemagglutinin, antibody CD3 presence...
To analyse predictors for relapses and number of attacks under different immunotherapies in patients with neuromyelitis optica spectrum disorder (NMOSD).This is a retrospective cohort study conducted neurology departments at 21 regional university hospitals Germany. Eligible participants were aquaporin-4-antibody-positive or aquaporin-4-antibody-negative NMOSD. Main outcome measures HRs from Cox proportional hazard regression models adjusted centre effects, important prognostic factors...
Background: Gender and age at onset are important epidemiological factors influencing prevalence, clinical presentation, treatment response in autoimmune diseases. Objective: To evaluate the impact of female sex fertile on aquaporin-4-antibody (AQP4-ab) status, attack localization, to patients with neuromyelitis optica (NMO) its spectrum disorders (neuromyelitis disorder (NMOSD)). Methods: Female-to-male ratios, diagnosis last visit (NMO vs NMOSD), treatment, outcome were compared according...
To investigate if patients with neuromyelitis optica spectrum disorder (NMOSD) develop subclinical visual pathway impairment independent of acute attacks.A total 548 longitudinally assessed full-field evoked potentials (VEP) 167 NMOSD from 16 centers were retrospectively evaluated for changes P100 latencies and P100-N140 amplitudes. Rates change in (RCL) amplitudes (RCA) over time analyzed each individual eye using linear regression compared generalized estimating equation models.The rates...
Abstract We embedded green fluorescent CD4+ T cells specific for myelin basic protein (MBP) (TMBP-GFP cells) in the immune system of syngeneic neonatal rats. These persisted animals entire observation period spanning &gt;2 years without affecting health hosts. They maintained a memory phenotype with low levels L-selectin and CD45RC, but high CD44. Although persisting numbers (0.01–0.1% lymph node they were sufficient to raise susceptibility toward clinical autoimmune disease....
CD147 is an activation induced glycoprotein that promotes the secretion and of matrix metalloproteinases (MMPs) upregulated during differentiation macrophages. Interestingly, some molecular functions rely on its glycosylation status: highly glycosylated forms induce MMPs whereas lowly inhibit MMP activation. Statins are hydroxy-methylglutaryl coenzyme A reductase inhibitors block synthesis mevalonate, thereby inhibiting all mevalonate-dependent pathways, including isoprenylation,...